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In this review, we provide a summary of recent progress in ontology mapping (OM) at a crucial time when
biomedical research is under a deluge of an increasing amount and variety of data. This is particularly
important for realising the full potential of semantically enabled or enriched applications and for
meaningful insights, such as drug discovery, using machine-learning technologies. We discuss challenges
and solutions for better ontology mappings, as well as how to select ontologies before their application. In
addition, we describe tools and algorithms for ontology mapping, including evaluation of tool capability
and quality of mappings. Finally, we outline the requirements for an ontology mapping service (OMS) and
the progress being made towards implementation of such sustainable services.Introduction
Biomedical research is under a deluge of an increasing amount and
variety of data. Diverse technologies enable more granular mea-
surements from the laboratory bench to the clinical bedside for
personalised treatments. To realise this promise, such data need to
be brought together to build consistent biological knowledge bases
[1]. As part of this process, different concepts, terminologies, and
data models need to be reconciled. This reconciliation is supported
by a variety of knowledge management resources, which cover a
continuous spectrum of ‘semantic expressivity’ (Fig. 1).
At one extreme, we have simple lists, such as controlled vocab-
ularies. Integration is significantly easier when different dataPlease cite this article in press as: Harrow, I. et al. Ontology mapping for semantically enabl
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https://doi.org/10.1016/j.drudis.2019.05.020 sources use terms from a standardised list, instead of free text.
Resources that have greater semantic expressivity enable more
support for integration and interoperability, for instance leverag-
ing synonyms or translating across languages. At the other ex-
treme of the semantic spectrum, we have ontologies. These are a
set of concepts in a subject area or domain that shows relations
between concepts represented by properties.
Ontologies go beyond lists, thesauri, and taxonomies to provide a
formal description of definitions of conceptual classes and their
relations (one example being their hierarchical structure). ‘Formal’
means that definitions are based on a logical framework, such as the
Web Ontology Language (OWL). This enables a representation of the
meaning of concepts that is machine processable, ultimately allowing
reasoning, generation of new knowledge, and automatic detection ofed applications, Drug Discov Today (2019), https://doi.org/10.1016/j.drudis.2019.05.020
icense (http://creativecommons.org/licenses/by/4.0/).
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FIGURE 1
The spectrum of semantic expressivity for knowledge management resources. Abbreviation: URI, Uniform Resource Identifier.
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Sinconsistencies in the semantic model [2]. In addition, Uniform
Resource Identifiers (URI) uniquely reference each class to support
machine processing and interoperability.
One of the strongest examples of a mature ontology in the
biomedical sciences is Gene Ontology (GO) [3,4], which is used
extensively by a multitude of applications and analytical tools [5].
Ideally, each domaininthe biomedical sciences shouldbesupported
by a single reference ontology [6], an idea that was originally a
strategic objective of the Open Biomedical Ontologies (OBO) con-
sortium [6]. However, the real situation is different and finds
numerous overlapping ontologies, each having their own contexts
of application. This creates problems of reconciliation and even
difficulties in selection of the most appropriate resource [7].
Overlap between ontologies happens for a variety of reasons.
One of these is that a single reference ontology often provides
insufficient coverage for a particular application, which gives rise
to the development of application ontologies, such as the Experi-
mental Factor Ontology (EFO). The EFO uses relevant parts of
reference ontologies and cross references (or mappings) between
them [8]. Mapping between ontologies expands the coverage
across large domains, such as anatomy, disease, phenotype, and
laboratory investigation. Mapping between ontologies in different
domains requires the discovery of the evidence for a relationship
through, for example, data or text mining [9,10].
Another reason is that many applications make use of classification
systems, such as Medical Subject Headings (MeSH), Enzyme Commis-
sion (E.C.) nomenclature, Anatomical Therapeutic Chemical Classifi-
cationofdrugs(ATC),orHumanGeneNomenclature(HGNC),which,
although powerful, were neverdesigned asontologies.However, itcan
be very useful to map between such classification systems and ontol-
ogies, which ontology-matching algorithms are able to do [11].
Although application ontologies and mapping to code lists can
be built by manual curation, it is desirable to augment this process
with ontology-matching algorithms [12]. These bring scalability
while reducing the cost of maintenance.
Application of ontologies and their mappings
Ontology application
Controlled vocabularies have been used for many decades, espe-
cially by industry, to ensure the consistency of metadata whilePlease cite this article in press as: Harrow, I. et al. Ontology mapping for semantically enabl
2 www.drugdiscoverytoday.comcollecting data of an experiment or conducting analysis, often in
laboratory information-management systems [13]. Seamlessly
integrated into applications, controlled vocabularies and ontolo-
gies can speed up the entry of data sets and facilitate the subse-
quent retrieval of data through simple search interfaces. This is
because experimental metadata for a biological assay can comprise
many elements, including creation date, experimenter, batch/
sample information (e.g., tissue or cell type, cell line, etc.), disease
or normal status, and treatment (stimulant, compound, placebo,
or time course) [14].
Ontologies already have an important role in annotating and
organising the vast wealth of experimental, clinical, and real-
world data and their day-to-day usage is well established in the
scientific community. Therefore, it is not surprising that the
important biomedical literature resource, PubMed, developed
and applies the MeSH taxonomy for indexing and searching
journal articles [15]. In pharmacovigilance, adverse events need
to be reported to the US Food and Drug Administration (FDA)
using the MedDRA ontology as a system to encode regulatory
information [16]. Furthermore, the FDA has mandated that the
Study Data Tabulation Model (SDTM), developed by the Clinical
Data Interchange Standards Consortium (CDISC), must be used as
the standard for the submission of study data. The controlled
terminologies of SDTM are integrated with the NCI Thesaurus
[17]. Real-world data provides a final example, where WHO clas-
sifications of disease, ICD-N, have been used for annotation [18].
Given that precision medicine, personalised healthcare, and trans-
lational medicine are increasingly driving modern research and
development in the biopharmaceutical industry, it is vital to
combine data from the vast number of public and private reposi-
tories using all these different classifications and ontologies.
Therefore, ontology mapping is intrinsically tied to data integra-
tion, which is crucial for the successful discovery and development
of innovative treatments of disease.
Ontologies are one of the mechanisms to encode the seman-
tics for an area of human knowledge in a machine-readable
manner [19,20]. They are vital for capturing meaningful rela-
tionships to allow users to search or browse relationships and to
identify patterns from analysis [21–24]. Consider modern search
engines, such as Google and Bing, which use minimal contexted applications, Drug Discov Today (2019), https://doi.org/10.1016/j.drudis.2019.05.020
Drug Discovery Today Volume 00, Number 00  June 2019 REVIEWS
DRUDIS-2475; No of Pages 8
R
M
A
TI
C
Sand, in the case of Wikipedia, users are presented with a disam-
biguation page to select the relevant results. This contrasts with
a search of scientific data and literature, which requires more
consistent and reliable results by harnessing controlled vocabu-
laries, classification systems, and ontologies (Fig. 1), especially
when thousands, if not millions, of results need to be processed
automatically. Consider the example of bone disease, as illus-
trated in Fig. 2, where we can see the positions of Legg–Calve–
Perthes disease and Coxa Magna in the MeSH hierarchy, without
any other prior knowledge. Such hierarchical structure of a
taxonomy or ontology can also help with the visualisation ofPlease cite this article in press as: Harrow, I. et al. Ontology mapping for semantically enabl
FIGURE 2
The relational position between two bone diseases, Legg–Calve–Perthes Diseasedata, so that a user can start with a broad class, such as bone
disease, and then move on to consider more specific, yet related,
diseases.
Ontologies and their mappings have a central role in open
semantically enabled applications, such as Open PHACTS [25]
and Open Targets [26]. Commercial examples of similar applica-
tions are Elsevier’s Pathway Studio [27] and Clarivate Analytics’
MetaCore/MetaBase [28]. In the case of Open Targets, this public
target validation application makes fundamental use of the EFO,
which has been developed and optimised to support such applica-
tions [29]. Many of these powerful applications use automateded applications, Drug Discov Today (2019), https://doi.org/10.1016/j.drudis.2019.05.020
Drug Discovery Today 
 and Coxa Magna, in the Medical Subject Heading (MeSH) hierarchy.
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for subject–verb–object triplets in scientific texts.
The evidence embedded in these applications is often integrated
with graphical visualisation and statistical analysis, where mapped
ontologies are the key components for being able to examine the
underlying biology of a hypothesis or an experiment [26,30–32].
The mapped ontologies vary by application, but typically include
GO, Disease Ontology (DO), Human Phenotype Ontology (HPO),
EFO, MeSH, and NCBI taxonomy. Crucially, such applications
provide links to the literature from which mappings were derived,
which is important to assess the confidence in such information
[30,33].
Mapping between ontologies
Ontology mapping (or matching) is central to providing semantic
access across aggregated data used in knowledge-based products
and services consumed by life science companies, academic insti-
tutions, and universities. When bringing together ontologies and
related resources (Fig. 1), we are faced with different scenarios
reflecting different use cases for mappings.
As mentioned earlier, often different ontologies are used to
annotate the same or similar domains, for example, HPO and
Mammalian Phenotype (MP) Ontology. These ontologies have
been developed independently by different communities or might
be customised to meet specific user needs. In this case, ontology
mapping finds equivalence (exact or synonymous matches) or
relationships in the hierarchy, which can be show narrow or broad
semantic similarity. Another similar example is DO, which is used
widely by the research community, whereas SNOMED CT is used
mostly by healthcare workers and clinicians, for example in the
National Health Service, UK (https://digital.nhs.uk/services/
terminology-and-classifications/snomed-ct). Translational appli-
cations require interoperability by mapping between these two
important ontologies, which has been approached successfully
through lexical mappings supplemented by Unified Medical
Language System (UMLS) concepts [34,35].
Another application of ontology mapping within a domain is
the predictive use of phenotype annotations in different model
organisms. For example, rare human gene mutations can be
annotated by relating homologous mutations to phenotypes in
model organisms for diagnosis of rare inherited diseases [36].
Finally, matching can also relate ontology terms between close-
ly related domains, such as disease and phenotypes [37]. In this
case, we are looking at establishing more generic relations between
concepts, effectively defining a knowledge network. This scenario
is a frequent task in life sciences, where ontology matching can
bridge different domains and support complex research questions.
Challenges and solutions for better mappings
Generating ontology mappings can provide several challenges.
Words in language can have ambiguous meanings that depend on
the context. For example, the English word ‘mole’, in anatomy it is
a skin feature, in chemistry it is a unit of measure, for an animal
there are numerous species of talpid ‘true’ mole or a distantly
related, marsupial mole or golden mole. Beyond the scientific
realm, mole can be a human surname, the name of various
villages, rivers, and creeks, and is also an embedded spy in
an organisation, and so on. This ambiguity means that it isPlease cite this article in press as: Harrow, I. et al. Ontology mapping for semantically enabl
4 www.drugdiscoverytoday.cominsufficient to simply match class names, terms, or labels for
successful ontology mapping. Therefore, it is important to make
use of context to resolve ambiguity, which includes background
knowledge and relations among concepts [38]. Another major
challenge to mapping ontologies is managing the consequences
of ontology dynamics, which reflect and represent how scientific
understanding evolves [1,38]. This means that any derived map-
pings have to be maintained, while making sure that source
identifiers and labels are retained. We expand on this challenge
in the OMS section of this review.
A common approach to tackling the challenge of mapping
between different ontologies is to map all the terms to a single
ontology or knowledge resource. Many source ontologies contain
embedded cross-references that can be used as curated matches to
another ontology. An Ontology of Biomedical Associations
(OBAN) is an example of such an approach, which was constructed
as a large-scale, generic term-association model to support con-
struction of a target validation knowledgebase [29]. PhenomeNET
is a further example, where species-specific phenotype ontologies
are mapped based on the overarching, anatomy ontology,
UBERON, which identifies equivalent phenotype features through
anatomical concepts across different species [39,40]. Similarly, the
Monarch Initiative has built a platform for mapping between
phenotypes and genotypes across species, and includes the Mon-
arch Merged Disease Ontology, called MONDO [41].
Guidance, principles, and simple rules for the selection
of ontologies
When several ontologies overlap to cover a scientific domain, we
are faced with the problem of how to select which ontology to use.
In clinical sciences, the best practice is mature enough to be
governed by authorities to meet government regulations, as de-
scribed earlier, whereas, in preclinical and translational research,
best practices and data standards tend to be less mature and even
absent. This situation promises to improve with the MIRO guide-
lines for Minimum Information for Reporting of an Ontology [42].
The Pistoia Guidelines were devised as a pragmatic step to support
the selection of ontologies before the application and mapping of
ontologies. These guidelines are available on a public wiki of
Ontologies Mapping Resources, hosted by the Pistoia Alliance
(https://pistoiaalliance.atlassian.net/wiki/spaces/PUB/pages/
43089928/Ontologies+Mapping+Resources). They comprise of
three types of guideline: general, technical, and content in Table
1. This table shows how the Pistoia guidelines align with the
principles of the Open Biological and Biomedical Ontologies
(OBO) Foundry (http://www.obofoundry.org), which are under
constant development and review by the OBO community. In
addition, Table 1 also shows alignment to the paper entitled ‘Ten
Simple Rules for Selecting a Bio-ontology’ published by Malone
et al. [7].
The suitability of ontologies for a particular application, such as
gene expression analysis or mapping between ontologies, can be
reviewed using the available rules and guidelines. The National
Center for Biomedical Ontology has developed a tool for this
purpose, called the Ontology Recommender 2.0 [43].
‘Sometimes an Ontology is Not Needed at All’ is the tenth
simple rule of Malone et al. [7]. This is because more light-weight
knowledge management systems might be sufficient (see Fig. 1 fored applications, Drug Discov Today (2019), https://doi.org/10.1016/j.drudis.2019.05.020
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Comparison of guidelines, principles, and simple rules for the selection of ontologies
Type Pistoia Guidelines OBO principles Simple rules paper [7]
Generic License Open Open
Maintenance Maintenance Active development
Versioning Versioning Previous versions available
Users Plurality of users documented; commitment to collaboration Development with the community
Locus of authority Locus of authority
Technical Format Format
URIs URIs Persistence of classes and relationships
Relations Relations
Textual definitions Textual definitions Textual definitions for domain experts
Documentation Documentation
Naming conventions Naming conventions Textual definitions for domain experts
Conserved URIs Persistence of classes and relationships
Content Content delineation Content delineation Specific domain
Content coverage Current understanding reflected
Content quality Textual definitions for domain experts
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should be driven by understanding the needs of the users.
Ontologies mapping tool evaluation
Tool requirements and capabilities
A set of minimal requirements can be used to compare the numerous
academic and commercial tools designed for mapping between
ontologies. These functional requirements comprise of three
aspects: (i) user Interface to include visualisation of source ontolo-
gies and mapping alignment editor; (ii) framework to include work-
flow and ontology matching (OM) algorithm; and (iii) import
ontologies or mappings and export of mappings (Fig. 3). These
requirements include elements of the ontology alignment life cycle
that have been described by Euzenat and Shvaiko ([44] Chapter 3).
Such functional requirements can be used to compare and
evaluate the capabilities of public and commercial ontology-
mapping tools. This process was undertaken in 2016, and found
that one academic tool (AML [45]) and two commercial tools
[Infotech Soft (http://infotechsoft.com) and Mondeca (http://
en.mondeca.com)] satisfied more than 80% of the functional
requirements illustrated in Fig. 3.Please cite this article in press as: Harrow, I. et al. Ontology mapping for semantically enabl
Ontology
Input
ontologies or
mappings
User Interface
Visualisation of
ontology structure 
Alignment editor
1
3
Output
mappings
FIGURE 3
Functional requirements of an ontology mapping tool.Evaluation of ontology matching algorithms
OM algorithms are computational tools that map between two
ontologies, and have wide application beyond life sciences [44].
The Ontology Alignment Evaluation Initiative (OAEI; http://oaei.
ontologymatching.org) is a mature and open annual challenge
that has operated since 2004. It provides a competitive platform to
showcase and evaluate the performance of latest algorithms.
It is useful to consider the different features and techniques used
by OM algorithms, which can be classified as summarised in Table
2 ([44] Chapter 3). They harness lexical features (e.g., different
names, synonyms, and definitions of concepts), structural, logical,
or hierarchical features (e.g., the relation one concept has with
other concepts within an ontology), extended information about
the source ontologies (e.g., usage in annotations), and exploit
background information (e.g., UMLS) [45].
OM algorithms produce a set of matches between the classes in
the two ontologies being mapped. Such matches might express
equivalence, binary, or multiple relations with a score of similari-
ty. The quality of the predicted matches of the mapping results will
depend on optimising the algorithm parameters, which will be
specific for the ontologies being mapped.ed applications, Drug Discov Today (2019), https://doi.org/10.1016/j.drudis.2019.05.020
 Mapping Tool
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TABLE 2
Features and techniques used by OM algorithms
Level Technical basis Short description of technique
Element String based Often used to match names, identifiers, and name descriptions of ontological entities
Language based Considers names as words in some natural languages, such as English
Constraint based Deals with internal constraints applied to definitions of entities, such as types, multiplicity of attributes, and keys
Informal resource based Deduces relations between ontology entities based on how they relate to each other
Formal resource based Makes use of formal resources, such as domain-specific ontologies, upper ontologies. and linked data
Structure Graph based Compares source ontologies (including database schemas and taxonomies) as nodes on labelled graphs
Taxonomy based Hierarchical classifications consider only the specialisation relation
Model based Matches source ontologies based on semantic interpretation
Instance based Compares sets of instances of classes to decide whether they match
Knowledge Fact or data based Exploits facts or data stored in relevant knowledgebase or database
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disease and phenotype ontologies in the OAEI 2016 challenge
(http://oaei.ontologymatching.org/2016). Predicted mappings
were compared to a ‘silver standard’ from a consensus vote, given
the absence of ‘gold standard’ mappings, in addition to limited
manual evaluation. Four systems (AML [45], FCA-Map [46], Log-
Map(Bio) [47], and PhenoMF [40]) gave the highest performance
for detection of equivalence matches, but all struggled to detect
semantic similarity [37]. It is clear that a combination of automat-
ed and manual curation is required to generate high-quality
mappings [48]. This is analogous to the workflow for protein
annotation, where a combination of automated and manual cura-
tion is used to produce and maintain the protein knowledgebase,
UniProt [49].
Toward services for ontology mappings
Service requirements
Ontologies are dynamic entities that evolve over time. Common
changes include: class addition; class deprecation; combination of
classes; and hierarchical relationships. Therefore, ontology map-
pings are not static resources and need to evolve in concert with
their source ontologies; it follows that any ontology mapping
needs to be provided not only as a one-off process, but also as
an ongoing service [1].
Whereas the most frequently used ontologies are openly acces-
sible, many researchers and organisations build their own ontol-
ogies, either to expand on a particular branch of a public ontology
or for areas that are not well served. Therefore, there are two key
use cases for an OMS: (i) mapping among public ontologies; and
(ii) mapping between public and internal ontologies. The former
can be achieved with a repository of mappings among popular
public ontologies, which has the benefit that it can manage
updates, utilise existing mappings, and generate new ones. The
second use-case can be approached by providing tooling such that
the user can generate bespoke mappings from their internal
ontologies to public ontologies as required.
For these and other use cases, an OMS should be able to be
used at all levels of an ontology, from single terms to entire
branches and ontologies. This give the flexibility that research-
ers need in daily search and integration tasks. It is useful to
contrast an OMS with an identifier mapping service, such as the
BridgeDb framework, which is focused on mapping between
database identifiers [50].Please cite this article in press as: Harrow, I. et al. Ontology mapping for semantically enabl
6 www.drugdiscoverytoday.comAn OMS for mapping among public ontologies should be able to
incorporate existing mapping sets, such as by utilising the cross-
references between ontologies that are commonly supplied as part
of the source ontology. An OMS should also harness an OM
algorithm, in addition to curation, to enable mapping at scale
across whole ontologies. Ideally, it should also allow the addition
of user-curated content and validation of predicted mappings,
assisted by ‘crowd-sourcing’, which has been used for ontology
validation [51].
Existing standards to represent alignments should be used by an
OMS ([44] Chapter 10). In addition, it should provide metadata for
mappings, which include: (i) dynamics: all ontologies and any
mappings between them will change over time; thus, the service
needs to reflect such dynamics using both through manual cura-
tion and automation by OM algorithms. A subset of metadata
should record such dynamics for interoperability and reuse; (ii)
provenance. Users should have clear information on the prove-
nance of any mapping, including ontology sources, version num-
ber, download date, and so on. Specifically, for each mapping, the
service should provide annotation with suitable metadata and
documentation, to enable interoperability and reuse; (iii) quality.
The service should provide the quality metrics for, and within,
mappings. This should include similarity scores for each match
(expected to range from exact and equivalent to close similarity to
broadly similar), an indication of confidence (e.g., validated or
not) and global metrics, such as precision (correctness from sam-
ples) and recall (missing matches compared to standard map-
pings); (iv) license limitations. Some ontologies, for example
SNOMED CT, have license restrictions, which might also apply
to derived products, such as mappings. These restrictions should
be captured as part of the OM metadata.
Implementing a prototype service
A prototype ontology mapping service has been implemented as
part of the Pistoia Alliance Ontologies Mapping project (https://
www.pistoiaalliance.org/projects/ontologies-mapping). The pri-
mary objective of this service is to provide mappings between
ontologies, building on existing EMBL-EBI services for the life
sciences [52]. In particular, the OM repository, OxO (https://
www.ebi.ac.uk/spot/oxo) is being developed to store mappings
(or cross-references) between terms from ontologies, vocabularies,
and coding standards. OxO stores cross-references, which are
curated mappings, embedded in >200 public ontologies hosteded applications, Drug Discov Today (2019), https://doi.org/10.1016/j.drudis.2019.05.020
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combine mapping data sets that are labelled in different ways.
Even if different standards are used to annotate data sets, they can
still be made interoperable through OM. Companies can use the
public-domain OMs in OxO to bridge the gap between public and
private research data.
The Pistoia Alliance prototype aimed to build on OxO through
development of an OM algorithm to predict mappings between
public ontologies hosted by OLS. The prototype service focussed
on the phenotype and disease ontology domain for ten mappings
between five public ontologies, namely: HPO, DO, Orphanet Rare
Disease Ontology (ORDO), MP, and MeSH. The mappings pre-
dicted by the algorithm, developed for the OMS, were compared
with silver-standard mappings from consensus voting between
top-performing algorithms in OAEI 2017 [37,53]. The predicted
mappings from this prototype service are stored in the OxO
repository, along with the curated cross-references (mappings)
embedded in all the public ontologies hosted by OLS.
TheOM algorithm (technical details will be disclosed in a planned
technical paper), powering the OMS stored in OxO, is able to detect
matches with high similarity score, where labels and synonyms are
equivalent or similar between ontologies. OxO also stores the man-
ually curated cross-references, which can be missed by the silver
standards. This powerful combination of predicted mappings from
an algorithm and curated mappings is an example of a solution that
can deliver a scalable and sustainable mapping service.
Concluding remarks
This review shows the impressive progress made over recent years
with engineering ontologies and their mappings by utilising mod-
ern tools and services. It describes how this progress enables better
support for semantically aware applications. We highlight crucialPlease cite this article in press as: Harrow, I. et al. Ontology mapping for semantically enablchallenges that must be recognised and overcome by public and
private enterprise working together in sustainable ways to deliver
the necessary tools and services. The important process of provid-
ing quality mappings between ontologies as a sustainable service
should be supported so that it can mature as a standardised and
consolidated activity.
The current flood of big data in the life sciences, especially from
‘omics sources, brings massive challenges for data management.
Semantic alignment and data standardisation are vital to solve if
we are going to harness modern technologies, such as machine
learning, for future drug discovery. These important challenges are
being met by the biopharma industry through the ongoing
implementation of the Findable, Accessible, Interoperable and
Reusable (FAIR) guiding principles for scientific data management
and governance, which make data ‘findable, accessible, interoper-
able, and reusable’ [54,55]. The interoperability principles of FAIR
are supported by the effective application of ontologies and their
mappings to underpin integration between many relevant sources
of data [2,56].
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